



INTESTINAL SURVIVAL AND ABSORPTION
OF EPIDERMAL GROWTH FACTOR IN THE
SUCKLING NEONATE.

A thesis submitted to the University of Adelaide,
South Australia, for the degree of
Doctor of Philosophy.

by

SUSAN MARY GALE. B.MED.SCI.(Hons.)

Adelaide Centre for Gene Technology,
Department of Biochemistry,
University of Adelaide,
South Australia. 5000.

April, 1988

as aded 207 88

TABLE OF CONTENTS

	Page
Thesis Abstract	1
Chapter One Historical Review	4
1.1 Introduction.	5
1.2 Definition of Growth Factors.	5
1.3 Mechanisms of Growth Factor Action.	6
1.4 Synergistic action of growth factors.	9
1.5 Epidermal growth factor: Discovery and characterization.	10
1.6 Growth factors in milk.	14
1.7 Differences between species in the growth factor profile in milk.	18
1.8 Changes in the growth-promoting activity of milk during lactation.	19
1.9 Site(s) of synthesis of milk growth factors.	22
1.10 Survival of growth factors in the neonatal intestine.	25
1.11 Absorption of growth factors and proteins in the neonatal intestine.	27
1.12 The Biological effects of EGF.	30
1.12(a) Biological effects of EGF on fetal and neonatal development.	30
1.12(b) Biological effects of EGF on skin and corneal epithelium.	31
1.12(c) Biological effects of EGF on the lung.	36
1.12(d) Biological effects of EGF on the gastrointestinal tract.	39

1.12(e)	The Biological effect of EGF on the mammary gland.	48
1.12(f)	Other Biological effects of EGF.	50
1.13	Biological role(s) of milk-derived EGF.	51
	Overall Conclusion.	56
Chapter Two	Scope of the Thesis.	64
Chapter Three	Acknowledgements.	68
Chapter Four	General Materials and Methods.	72
	Growth factors.	73
	Radiolabelling of growth factors.	73
	Specific polyclonal antisera against mEGF and hEGF.	77
	Materials for radioimmunoassays and radioreceptor assays.	78
	Radioimmunoassays for mEGF and hEGF.	78
	Radioreceptor assays for EGF.	80
Chapter Five	Properties of synthetic-gene recombinant human epidermal growth factor: comparison with the natural growth factor from human urine and milk.	82
	Abstract.	84
	Introduction.	85
	<u>Materials and Methods.</u>	86
	Growth factors.	86
	Iodination of EGF.	86
	Radioreceptor assays.	87
	Radioimmunoassays.	87
	Measurement of rates of protein synthesis and degradation in cultured fibroblasts.	87

<u>Results.</u>	89
Radioreceptor assays.	89
Radioimmunoassays.	91
Protein synthesis and degradation in cultured fibroblasts.	92
<u>Discussion.</u>	93
Chapter Six	
Preparation of monoclonal antibodies and polyclonal antiserum directed against synthetic-gene recombinant hEGF: Characterization of monoclonal antibodies and comparison with the polyclonal antiserum.	105
<u>Abstract.</u>	106
<u>Introduction.</u>	107
<u>Materials and Methods.</u>	110
Growth factors.	110
Radiolabelled EGF.	110
Preparation of Polyclonal Antiserum against hEGF.	110
Preparation of Monoclonal antibodies against hEGF.	110
Immunization of mice for monoclonal antibody production.	110
Solid-phase radioimmunoassay (SPRIA).	111
Enzyme-linked immunosorbent assay (ELISA).	112
Cell Hybridization and Selection of Hybrid clones.	113
Procedure for the identification of each hybridoma monoclonal antibody isotype.	115

Purification of ascitic fluid and polyclonal serum by (protein A) - Sepharose affinity chromatography.	116
Fluid phase radioimmunoassay.	117
Preparation and isolation of S-carboxymethylated hEGF and mEGF.	118
Epitope mapping of monoclonal antibodies and specific polyclonal antiserum using peptide synthesis.	120

Results.

Generation of hEGF monoclonal antibodies.	121
Production of specific anti-hEGF polyclonal serum.	122
Characterization of the monoclonal antibodies.	122
- determination of antibody isotype.	122
- purification of ascitic fluid by protein A - affinity chromatography.	123
- reactivity of monoclonal antibodies with mouse and human EGF.	123
- reactivity of monoclonal antibodies with 3 species of radiolabelled hEGF.	124
- production of S-carboxymethylated hEGF and mEGF.	126
- comparison of the reactivity of the monoclonal antibodies and polyclonal antiserum with the native and S-carboxymethylated forms of hEGF.	126

- use of peptide synthesis to identify hEGF monoclonal antibody and specific polyclonal antiserum epitopes.	128
<u>Discussion.</u>	129
Chapter Seven. The Relationship between dietary EGF intake and urinary EGF excretion in the premature infant: an indirect method of detecting EGF uptake by the human neonatal intestine.	157
<u>Abstract.</u>	159
<u>Introduction.</u>	160
<u>Materials and Methods.</u>	161
- infants.	161
- children and adults.	161
- preparation of urine samples prior to radioimmunoassay.	161
- solid-phase radioimmunoassay.	162
- creatinine determination.	163
- statistics.	163
<u>Results.</u>	164
- influence of dietary EGF on urinary EGF excretion.	164
- influence of age on urinary EGF excretion.	165
<u>Discussion.</u>	165
Chapter Eight. A Quantitative assessment of the intestinal absorption of immunologically-intact EGF using the autoperfused lamb intestine method.	178
<u>Abstract.</u>	180
<u>Introduction.</u>	181

<u>Materials and Methods.</u>	183
- animals.	184
- radio-labelled compounds.	183
- animals.	184
- radio-labelled compounds.	184
- insertion of chronic gastric and re-entrant small intestinal catheters to determine the survival of ingested EGF.	184
- auto-perfused lamb intestine.	186
- EGF radioimmunoassays.	191
- IgG radioimmunoassays.	191
<u>Results.</u>	192
- integrity of EGF in the small intestine of the lamb following intra-gastric administration.	192
- absorption of EGF by the auto- perfused lamb intestine.	193
(1) perfusion characteristics.	194
(2) radioimmunoassays.	195
(3) intestinal absorption of EGF and IgG.	196
<u>Discussion.</u>	198
Chapter Nine. Conclusions.	233
Bibliography.	242

THESIS ABSTRACT

In addition to meeting the requirements for protein and calories, milk contains a wide spectrum of growth factors which stimulate growth and differentiation of various tissues both in vitro and in vivo. These growth factors include insulin, epidermal growth factor (EGF), and insulin-like growth factors. Human milk appears to be particularly rich in EGF, the concentrations exceeding adult serum levels by 1000-fold in day 1 milk and 100-fold in milk expressed at later stages of lactation. This has led to the hypothesis that milk-derived EGF may play an important role in neonatal growth and development.

The physiological role of milk-derived EGF in the suckling neonate may only be assessed after quantitative studies on both the survival and absorption of orally-administered EGF in the neonatal intestine. In this thesis, the fate of orally-administered EGF was examined both in the human infant and in an experimental animal model, the newborn lamb. Since a quantitative evaluation of EGF metabolism is not feasible in the human neonate, the intestinal survival and absorption of EGF was assessed by a study of the relationship between the level of dietary EGF intake and urinary EGF excretion in premature infants. This indirect method provided a non-invasive, yet ethically practical evaluation of EGF uptake. A quantitative examination of both the intestinal survival and the rate of intestinal absorption of EGF was examined using the newborn lamb as a model of the human infant.

The results of the human study were found to be consistent with the hypothesis that EGF crosses the gastrointestinal wall to enter the general circulation.

Premature infants receiving higher levels of EGF in their diet showed greater urinary EGF excretion after the second postnatal week. Whilst this finding could also be explained by an indirect effect of some breast milk component on rates of endogenous EGF synthesis, they are nonetheless consistent with the absorption of intact EGF across the neonatal intestine.

The lamb was used as an experimental animal model of the human infant to study both the intestinal survival and absorption of EGF. To assess intestinal survival, reentrant catheters were inserted into the mid-small intestine of suckling lambs. A minimum of 15-30% of intragastric ^{125}I -labelled EGF reached the mid-small intestine as immunologically intact EGF, providing strong evidence that a substantial proportion of milk-derived EGF would reach the small intestine intact.

Intestinal uptake of unlabelled EGF was measured in vivo using the autoperfused lamb intestine. In lambs of age 1-18 days, immunologically intact EGF was absorbed into blood but not lymph at rates that showed no correlation with the age of the lamb. The rates of absorption were low, resulting in a mean venous blood concentration of 0.02nM following infusion of 50 μg EGF into a 20cm segment of gut. Given these low concentrations plus the known rapid clearance of EGF from plasma by various organs including the liver, it appears that very little luminal EGF would reach peripheral tissues intact in the neonatal lamb.

The studies in lambs therefore suggest that the direct growth-promoting actions of milk-derived EGF in the suckling infant are likely to be confined to the gastrointestinal tract and possibly the liver. Any actions in other tissues

are more likely to be mediated by secondary responses to the actions of EGF in the gut and the liver.